{"schema":"sb.node.v1","id":"sb:e/2e66f10ad26f5e5d164efc6e","kind":"entity","label":{"text":"fda-approved","locale":"en"},"identity":{"anchor":"label:en:fda-approved","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T20:34:57.810068+00:00","snapshot":"deploy 04403dd1b6ff6ffe00b03195c3da75dd204003f6"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":156,"separatePublishers":48,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.474: about 53% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma","auto"],"activeDays":43,"assertions":{"regulatory-approval":56,"meeting-visit":5,"launch-release":4,"funding-round":4,"ipo-listing":2,"sports-outcome":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/6ead3d60fa6b74b8cef3ec8a","kind":"observation","label":"BioPharma Dive · 2026-10-03 · Lilly, Foghorn part ways; Wave’s FDA-approved plans","url":"https://www.biopharmadive.com/news/foghorn-eli-lilly-wave-samsung-bioepis-teva-varda-hatteras/831918/"},{"id":"sb:o/173e56f8a0de845f53721d73","kind":"observation","label":"FDA · 2026-10-01 · Drug Safety-related Labeling Changes (SrLC) Database Overview: Updates to Safety Information in FDA-Approved Prescription Drug Labeling","url":"http://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-related-labeling-changes-srlc-database-overview-updates-safety-information-fda-approved"},{"id":"sb:o/6394e3fb3efb6ddd34f69dc4","kind":"observation","label":"AG Daily · 2026-09-23 · Scientists test FDA-approved drug against New World screwworm","url":"https://www.agdaily.com/news/scientists-test-fda-approved-drug-against-new-world-screwworm/"},{"id":"sb:o/e9afed359ee34d29fb2fa042","kind":"observation","label":"PR Newswire · 2026-09-12 · Meant Health Expands Telehealth Access to FDA-Approved GLP-1 Prescriptions, Including Ozempic®","url":"https://www.prnewswire.com/news-releases/meant-health-expands-telehealth-access-to-fda-approved-glp-1-prescriptions-including-ozempic-302876301.html"},{"id":"sb:o/2ba354bee594166e7203b751","kind":"observation","label":"FDA Drug News · 2026-04-17 · [APPROVAL] First FDA-Approved Treatment for Patients with Focal Segmental Glomerulosclerosis—A Rare Kidney Condition","url":"http://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition"},{"id":"sb:o/1c6a642d6be36b4004776b41","kind":"observation","label":"FDA Press Releases · 2026-04-06 · [APPROVAL] FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs","url":"http://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"},{"id":"sb:o/84fa1871d1bf2fc4acf60898","kind":"observation","label":"The Well News · 2026-10-07 · Policymakers Must Take Action to Preserve the Purpose of Medication Compounding and the Integrity of the Medicine Supply Chain","url":"https://www.thewellnews.com/opinions/policymakers-must-take-action-to-preserve-the-purpose-of-medication-compounding-and-the-integrity-of-the-medicine-supply-chain/"},{"id":"sb:o/01a40a388445cd2dcedb05d9","kind":"observation","label":"FDA · 2026-10-07 · Online Generic Medicine/www.onlinegenericmedicine.com - 737806 - 09/23/2026","url":"http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026"},{"id":"sb:o/33743f8b01eaa3ff958a9c7e","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-07 · From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1941788"},{"id":"sb:o/acdd3327df1a1c659af6ea90","kind":"observation","label":"TIME · 2026-10-07 · Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?","url":"https://time.com/article/2026/10/07/compounding-pharmacies-weight-loss-drugs/"}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (156 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d56f370b9cf8f51a5fd14043"},{"kind":"relation","label":"co-mentioned with drug administration (54 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d25098be97510cd0973026ed"},{"kind":"relation","label":"co-mentioned with united states (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4286a82a7e2fcfb5d334c1bc"},{"kind":"relation","label":"co-mentioned with u.s. food (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9d592a8d4a25025ea538b04d"},{"kind":"relation","label":"co-mentioned with clinical trial (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/41ed5b753cd85411dbe694f4"},{"kind":"relation","label":"co-mentioned with ai (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/64f9c7b081bace4b13b74492"},{"kind":"relation","label":"co-mentioned with cder (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ef05d6f24c17824aad486618"},{"kind":"relation","label":"co-mentioned with public health (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fd66f1165fc806afa54fe808"},{"kind":"relation","label":"co-mentioned with size (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0a2f395a460ab5a26e124aae"},{"kind":"relation","label":"co-mentioned with glp-1 (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/66354fef3435b8682320f928"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/2e66f10ad26f5e5d164efc6e","mcp":"traverse {\"id\":\"sb:e/2e66f10ad26f5e5d164efc6e\"}","page":"/entity/fda-approved/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2e66f10ad26f5e5d164efc6e\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2e66f10ad26f5e5d164efc6e\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2e66f10ad26f5e5d164efc6e\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2e66f10ad26f5e5d164efc6e\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}